Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved

Introduction: Obesity is a global health challenge, and pharmacologic options are emerging. Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 analogue, has been shown to induce weight loss in clinical trials, but real-world effectiveness data are scarce. Methods:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Liesbet Trenson, Sander Trenson, Falco van Nes, Carolien Moyson, Matthias Lannoo, Ellen Deleus, Ann Meulemans, Christophe Matthys, Ann Mertens, Bart Van der Schueren, Roman Vangoitsenhoven
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
Acceso en línea:https://doaj.org/article/012fee322dbd4e18b690bd93835e9349
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!